# ClinicalTrials.gov record NCT02146079

> PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct02146079-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-04-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02146079-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02146079-semaglutide-v1.json
- Content SHA-256: `2fdd533f2eb98773eb9ebe3b871de090291a60cda28ec012861f54b7ab758d37`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02146079 ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

## Sources

<a id="source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e"></a>
- **ClinicalTrials.gov record NCT02146079 · retained source version 2018-04-18:169bfd91cc0e8b337d89fae36fec19ae6ab167c393a9db011aca39bfb2d2eb6e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02146079) (`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02146079." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02146079-semaglutide-v1.json SHA-256: 2fdd533f2eb98773eb9ebe3b871de090291a60cda28ec012861f54b7ab758d37.